<p>Photocure ASA has announced that its partner, Asieris Pharmaceuticals, has published the results of an international multicenter Phase III clinical study for APL-1702 (Cevira®), a non-surgical treatment candidate for cervical High-Grade Squamous Intraepithelial Lesion (HSIL). The study data have been published online in Med, a flagship medical journal from Cell Press. Cevira is currently under regulatory review in China. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Photocure ASA published the original content used to generate this news brief on October 10, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

688176

<p>Photocure ASA announced that its partner, Asieris Pharmaceuticals, has published Phase III clinical trial results for Cevira (APL-1702), a non-surgical treatment for cervical HSIL, in the medical journal Med. The study is currently under regulatory review in China.</p>

Photocure ASA partner Asieris publishes phase III clinical trial results for Cevira in Med journal